Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series.

about

Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.

P2860

Q36502730-B9466F20-A6C8-4C74-B22F-58B199D33F10

P2860

Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series.

Item

http://www.wikidata.org/entity/Q36024666

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Pathological response rate in ...... ekly docetaxel: a case series.

@ast

Pathological response rate in ...... ekly docetaxel: a case series.

@en

type

Item

label

Pathological response rate in ...... ekly docetaxel: a case series.

@ast

Pathological response rate in ...... ekly docetaxel: a case series.

@en

prefLabel

Pathological response rate in ...... ekly docetaxel: a case series.

@ast

Pathological response rate in ...... ekly docetaxel: a case series.

@en

P1476

Pathological response rate in ...... ekly docetaxel: a case series.

@en

P2093

Fumi Masumoto

http://www.w3.org/2001/XMLSchema#string

Hirotoshi Takahashi

http://www.w3.org/2001/XMLSchema#string

Hiroyasu Yamashiro

http://www.w3.org/2001/XMLSchema#string

Misao Atsumi

http://www.w3.org/2001/XMLSchema#string

Nao Morii

http://www.w3.org/2001/XMLSchema#string

Shinji Ozaki

http://www.w3.org/2001/XMLSchema#string

Takayoshi Kiba

http://www.w3.org/2001/XMLSchema#string

P2860

Supervised risk predictor of breast cancer based on intrinsic subtypes

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype.

CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.

Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7.

Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.

Options and limits of surgery after pre-operative chemotherapy in breast cancer.

P304

245-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BCTT.S90975

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26357489

http://www.w3.org/2001/XMLSchema#string

P932

4559240

http://www.w3.org/2001/XMLSchema#string

Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series.

about

P2860

P2860

Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932